Drug intelligence / Profile preview

AVTX-406

Development stage: Unknown
Lead developer: ES Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AVTX-406 is a small molecule drug that acts as a selective catechol-O-methyltransferase (COMT) inhibitor. It was originally discovered by Merck & Co and further developed by Avalo Therapeutics (formerly Cerecor). The primary mechanism of action is inhibition of the COMT enzyme, which plays a role in the metabolism of catecholamines such as dopamine. This neuro-selective COMT inhibitor was being developed as an oral adjunctive therapy to levodopa/carbidopa for patients with Parkinson’s disease experiencing "off-periods" in symptom management. It has also been considered for depressive disorders[1][7].

Other names: AVTX-406AVTX406AVTX 406CERC 425CERC425CERC-425CERC-406CERC406CERC 406

Targets

COMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on AVTX-406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVTX-406.

Explore the full profile